KRAS and pancreatic neoplasm: Combinatorial approaches targeting multiple KRAS effector pathways, such as MAP kinase and PI3K/AKT, are considered, along with therapies addressing the adaptability of metabolic pathways and the heterogeneity of pancreatic tumors.